ImCheck fetches €96M for antibodies that activate immune cells against cancer

ImCheck Therapeutics aims to broaden the reach of cancer immunotherapy with antibody drugs that activate a rare but powerful type of immune cell called gamma delta T cells. The biotech has unveiled €96 million to advance its pipeline, including a lead candidate in development for both liquid and solid tumors.

Leave a Reply

Your email address will not be published. Required fields are marked *